Background: Delirium is a potentially life-threatening syndrome that is particularly common in elderly hospitalized patients, especially those with preexisting neurologic disorders. Nonpharmacological tactics can reduce the incidence and severity of delirium in acute care settings and antipsychotic drugs are widely used to treat established delirium. More effective preventive strategies could notably impact morbidity, mortality, and health care costs. Objective: To determine whether antipsychotic drug prophylaxis reduces the incidence and severity of postoperative delirium in at-risk elderly patients. Methods: We addressed the objective through development of a structured critically appraised topic that included a clinical scenario, structured question, search strategy, critical appraisal, results, evidence summary, commentary, and conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of cognitive disorders. Results: One randomized controlled trial addressed the question. In at-risk patients aged Ͼ70 years, oral haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day, did not alter the incidence of postoperative delirium (15.1%) compared with placebo (16.5%; relative risk 0.91; 95% confidence interval 0.59 -1.44). However, the study was underpowered for this primary outcome, possibly because both groups received nonpharmacological delirium prevention strategies. Haloperidol significantly reduced delirium severity ratings, delirium duration (from a mean of 11.8 to 5.4 days), and length of hospital stay in affected participants (from 22.6 to 17.1 day). Conclusion: Adjunctive low-dose haloperidol prophylaxis reduces delirium severity, duration, and subsequent hospitalization length in elderly at-risk patients. Further study is needed to determine the optimal pharmacological approach, combination with nonpharmacological strategies, and generalizability to other settings.
A 75-year-old man enjoyed good general health, but his family noted that he was becoming increasingly forgetful. One year ago, he underwent a genitourinary operation and was confused for 12 hours after the procedure. Six months ago, he became temporarily disoriented and mildly agitated during a vacation to an unfamiliar city. The day prior to admission, he fell and fractured his left femur and was awaiting surgery. His general and neurological examinations were normal, with the exception that his Mini-Mental Status Examination score was 23 of 30. Preoperative delirium prophylaxis was considered.
BACKGROUND
Delirium is defined as a disturbance of consciousness with reduced ability to focus, sustain, or shift attention which develops over hours to days, fluctuates, and is caused by a general medical condition. 1 Acute care and postoperative settings are most commonly associated with delirium. Risk factors for postoperative delirium include older age, cognitive impairment, prior delirium, preoperative narcotic use, abnormal sodium potassium or glucose, psychotropic drug use, apolipoprotein 4 carrier status, postoperative hypotension, and tobacco use. [2] [3] [4] [5] [6] [7] The consequences of delirium in elderly hospitalized patients include prolonged hospital stay and increased rates of institutionalization and mortality. 8 -10 Furthermore, half of all days in hospital in the elderly are attributable to delirium, at an estimated cost of $6.9 billion in 2004. 11 Effective preventive strategies, therefore, could result in substantial health quality and cost gains.
Strategies to prevent delirium in acute care and postoperative settings include multicomponent risk factor modification and pharmacological therapies. Management of 6 risk factors for delirium (cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration) reduced delirium incidence (number needed-totreat [NNT] ϭ 20), but not severity or duration, in a prospective study comparing an intervention ward to 2 usual care wards in a teaching hospital. 12 A randomized controlled trial (RCT) showed that, compared with usual care, early geriatrician intervention for elderly patients admitted for emergent repair of hip fracture could reduce delirium incidence (NNT ϭ 6) and severity. 13 Systematic attention was given to the domains of oxygenation, fluid and electrolyte balance, pain management, reduction in psychoactive drug use, bowel and bladder function, nutrition, early mobilization, and prevention of postoperative complications.
Antipsychotic drugs are recommended and widely used to treat established delirium, a practice supported to some degree by RCT-level evidence. 14, 15 There is interest in the ability of a wide range of drug therapies with a variety of different mechanisms to prevent delirium or minimize its effects. 11
CLINICAL QUESTION
Does antipsychotic prophylaxis, compared with placebo, prevent or reduce the severity of postoperative delirium in at-risk elderly patients?
SEARCH STRATEGY
Ovid MEDLINE database was searched for the time period of 1996 to November Week 2 2007. MeSH (Medical Subject Heading) terms "delirium" (yield 3465 articles), "postoperative complications" (yield 315,613), and "antipsychotic agents" (yield 87,720) were exploded and combined using the Boolean "and" resulting in a yield of 33 citations. A search filter for therapy, emphasizing relevancy, was applied to locate RCTs and yielded 2 articles. The article by Kalisvaart et al 16 was selected because it is the only published RCT evaluating an antipsychotic drug for delirium prevention. Broader search strategies that used additional diagnostic terms (such as "acute confusion," "acute confusional state," "acute brain syndrome," or "encephalopathy") and implementation of the same search strategies in the EMBASE and Cochrane Library databases detected no additional relevant articles.
EVIDENCE, RESULTS, AND CRITICAL APPRAISAL
Kalisvaart et al conducted a prospective, randomized, double-blind, placebo-controlled trial evaluating low-dose haloperidol prophylaxis for delirium prevention in elderly patients awaiting nonelective hip surgery. Participants were recruited from orthopedic and surgical units at a large hospital in the Netherlands between August 2000 and August 2002. Of 681 admissions during that period, 603 patients were screened and their delirium risk estimated based on the presence of 4 putative risk factors: visual impairment (worse than 20 of 70), severity of illness (Acute Physiology Age and Chronic Health Examination II score scale Ն16; range of the scale is from 0 ϭ no acute health issues to 70 ϭ severe acute health issues), cognitive impairment (Mini-Mental Status Examination score Յ24), and index of dehydration (ratio of blood urea nitrogen to creatinine Ն18). 17 Delirium risk was stratified as intermediate (1-2 risk factors present) or high (3-4 risk factors present) and those with no risk factors were excluded from participation. Other exclusion criteria included current delirium, use of cholinesterase inhibitors, history of parkinsonism or epilepsy, levodopa treatment, and prolonged QTc interval on electrocardiogram.
Four hundred eighty-two patients were study-eligible, but 52 declined participation; therefore, 430 patients were ultimately randomized to receive oral haloperidol 0.5 mg TID for up to 72 hours preoperatively and for 3 days postoperatively. All participants underwent preoperative geriatric assessment that included a structured multicomponent protocol (geriatric medical attention; enhancement of orientation and cognition; sensory and mobility-improving advice; attention to pain, sleep issues, and fluid and food intake; and patient, family, and nursing staff education). If delirium occurred, treatment with thrice-daily haloperidol, lorazepam, or both was administered per hospital protocol.
The primary outcome measure was presence or absence of postoperative delirium as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and Confusion Assessment Method (CAM) criteria. 1, 18 Secondary outcome measures included delirium severity, rated with the Delirium Rating Scale, revised version-98 ͓DRS-R-98, range 0 (no severity)-45 (high severity)͔, duration of delirium, and length of hospital stay. Intervention adherence was recorded daily by clinical staff independent of the researchers. Trained research staff performed all baseline and outcome assessments.
Three hundred and ninety-five participants (91.9%) completed the study with similar withdrawal rates (9% and 13%) in each group and protocol adherence rates were excellent. The intention-to-treat analysis included the 430 randomized patients and the baseline demographic and clinical characteristics of each group were similar. The mean number of delirium risk factors was 2 and Acute Physiology Age and Chronic Health Examination II scores were relatively low, indicating that most patients were at intermediate delirium risk and were in generally good health, awaiting nonelective surgery. The proportions of participants at intermediate and high delirium risk were 84.4% and 15.6% in the haloperidoltreated group and 83.8% and 16.2% in the placebo group.
Results are summarized in Table 1 . The overall inci- (95% CI 0%-4.4%) of low-risk patients screened later developed delirium; in sum, these data support the validity of the predictive screening tool. There were no significant differences between the delirium incidences when comparing haloperidol and placebo groups overall, nor when the subgroups of intermediate and high-risk were evaluated separately. However, the severity and duration of delirium, as well as the length of hospital stay, were reduced in patients receiving haloperidol. No drug-related adverse events were noted, including specific assessments for extrapyramidal symptoms and akathisia.
The study is generally well designed with clear descriptions of the protocol setting, patient spectrum, study entry criteria, and efficacy and adverse event outcome assessments. Randomization, allocation, concealment, and blinding procedures were all described satisfactorily. Outcome assessments were performed by blinded researchers and the withdrawal rate was low and relatively well balanced between study groups. The main statistical analysis was done by intention-to-treat and the magnitude and precision of effects are reported.
A major limitation of the evaluation of the primary study outcome is the unexpectedly low frequency of postoperative delirium in both the experimental and placebo groups. As the authors acknowledge, this is very likely owing to a combination of the overrepresentation of intermediate risk patients and the availability of nonpharmacological strategies, which have been demonstrated to have significant benefit in reducing delirium incidence, to both study arms. As a result, the protocol has excellent internal validity but insufficient power to detect an effect on the primary outcome.
Clinical Bottom Lines
• In at-risk patients aged Ͼ70 years, oral haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day, did not alter the incidence of postoperative delirium (15.1%) compared with placebo (16.5%; relative risk 0.91; 95% CI 0.59 -1.44) but the study was underpowered for this primary outcome. • Haloperidol had a statistically significant benefit on delirium severity as measured by an outcome instrument that has been validated for diagnostic purposes. • Compared with placebo, haloperidol prophylaxis was associated with significant reductions in the duration of delirium ͓mean decrease 6.4 (4.0 -8.0) days͔ and hospital stay ͓mean decrease 5.5 (4.1-7.8) days͔, possibly indicating that prophylaxis may facilitate earlier and more rapid treatment of breakthrough delirium symptoms. • Further studies of generalizable pharmacologic strategies for delirium prevention are needed.
DISCUSSION
The study by Kalisvaart et al represents the best current evidence supporting the use of antipsychotic prophylaxis in at-risk hospitalized elderly patients as an adjunct to nonpharmacological strategies. Although an effect on the primary outcome was not achieved, the study demonstrated a consistent effect of low-dose haloperidol on several secondary measures, such as delirium severity, duration, and length of hospitalization. The findings also suggest that low-dose haloperidol prophylaxis may make breakthrough delirium easier to treat, although the data concerning delirium treatment are not presented. Furthermore, the study data validate the prognostic utility of the risk factors used to stratify patients into intermediate and high-risk groups.
Some limitations remain regarding both interpretation of the evidence and its generalizability. The dose of haloperidol used in this study population seems to reduce delirium severity as measured by the Delirium Rating Scale. This scale has been validated for diagnosis and measurement of delirium severity, but whether the 4-point difference between treatment groups is clinically significant is not clear. Furthermore, the measurement of hospital stay duration is a less robust outcome, subject to influence by medical comorbidities, medication use, hospital protocols, availability of family and other support, and international differences. The hospital stays of the patients in this study seem long by North American standards. Finally, whether the results of this study can be applied to nonorthopedic surgical patients, nonsurgical patients, and those with neurologic comorbidities is not clear. Importantly, patients with more severe cognitive impairment or parkinsonism very likely comprise a high-risk group but were excluded from participation in this study.
Kalisvaart et al chose a low dose of haloperidol to balance potential efficacy with a low rate of adverse effects, especially extrapyramidal symptoms, which tend to occur with daily doses of more than 3 mg. Although there has been recent controversy about an increased risk of mortality in patients taking either typical or atypical antipsychotic drugs, it is important to note that the low-dose, temporary regimen used in this study is likely to carry low risk. There were no adverse events related to haloperidol in this study. It is not known whether the newer atypical antipsychotics have advantages with respect to either efficacy or safety for delirium prophylaxis.
The magnitude of benefit achievable by risk factor modification and other nonpharmacological approaches to delirium prevention are likely limited by practical concerns, such as lack of nursing or other resources needed to implement the programs, and because of the organic nature of delirium, which often occurs against a background of neurodegenerative disease. Further progress in delirium prevention will likely require adjunctive pharmacological strategies. Clinical research in this field is still immature but being explored with agents as diverse as gabapentin, 19 donepezil, 20 and melatonin. 21 When combined with systematic nonpharmacological preventive strategies, incorporation of routine drug prophylaxis for at-risk elderly individuals, such as the intermediate-risk patient we presented in our case scenario, could pay large dividends.
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